Relapsed Refractory Diffuse Large B Cell Lymphoma C0855112
An aggressive blood cancer that has either returned or stopped responding to treatment. Requires newer therapeutic approaches with varying outcomes.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Painless lymphadenopathy
Unexplained fever
Bone pain
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Night sweats
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy with clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Salvation chemotherapy regimen
Intensive chemotherapy combinations such as R-ICE, R-DHAP, or polatuzumab-based regimens designed to achieve remission in relapsed or refractory disease. Treatment is typically administered in cycles with close monitoring for response and toxicity.
CAR-T cell therapy
Chimeric antigen receptor T-cell therapy using the patient's own engineered immune cells to target lymphoma cells. This innovative treatment offers potential for durable responses in patients who have failed multiple prior therapies.
Additional treatment options
Autologous stem cell transplantation
High-dose chemotherapy followed by rescue with previously collected stem cells. This consolidates remission achieved through salvage therapy and offers potential for long-term disease control in eligible patients.
procedureTargeted therapy agents
Incorporation of novel agents such as bispecific antibodies, antibody-drug conjugates, or small molecule inhibitors targeting specific lymphoma pathways. These may be used in combination with chemotherapy or as single agents in later lines.
medicationResponse assessment and surveillance
Regular imaging studies and biopsy confirmation of treatment response throughout the treatment course. FDG-PET scans and CT imaging help evaluate disease status and guide treatment decisions at each stage.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Relapsed Refractory Diffuse Large B Cell Lymphoma C0855112?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Coiffier B, Salles G, Haioun C. NCCN Guidelines: Management of Relapsed Refractory Diffuse Large B Cell Lymphoma. J Natl Compr Canc Netw. 2022.
Gisselbrecht C, Glass B, Mounier N. Salvage regimens for relapsed/refractory diffuse large B-cell lymphoma. Blood Rev. 2018.
Crump M, Neelapu SS, Farooq U. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2021.
Kane SV, Kurita Y, Chen L. Anti-CD19 CAR T-cell therapy for relapsed refractory DLBCL: systematic review and meta-analysis. Lancet Haematol. 2023.
Medication Comparisons
Compare medications used to treat Relapsed Refractory Diffuse Large B Cell Lymphoma C0855112. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy